GPC3 is an oncofetal antigen highly expressed in hepatocellular carcinoma (HCC) but minimally expressed in adult normal tissues, except the placenta. Cytovia Therapeutics Inc. has presented preclinical data on CYT-303, a bispecific natural killer (NK) engager targeting NK cell-activating receptor NKp46 and GPC3 expressed in tumor cells.